Q1 2023 Results
Company overview
Financial review
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
iptacopan - CFB inhibitor
NCT04889430 APPELHUS (CLNP023F12301)
Conclusions
Atypical haemolytic uraemic syndrome
Indication
Phase
Phase 3
Patients
50
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Percentage of participants with complete TMA response without the use of
PE/PI and anti-C5 antibody
Single arm open-label with 50 adult patients receiving 200mg oral twice daily
doses of iptacopan
Adult patients with aHUS who are treatment naive to complement inhibitor
therapy (including anti-C5 antibody)
Readout
Milestone(s)
2025
Publication
TBD
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
References
Abbreviations
Other
71 Investor Relations | Q1 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation